We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+6.82%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.27B
AUM Growth
+$432M
Cap. Flow
+$259M
Cap. Flow %
7.92%
Top 10 Hldgs %
37.03%
Holding
113
New
28
Increased
27
Reduced
21
Closed
27

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$111M
2
MYGN icon
Myriad Genetics
MYGN
+$77.2M
3
BAX icon
Baxter International
BAX
+$36.4M
4
BFLY icon
Butterfly Network
BFLY
+$36.2M
5
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$35.7M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$52.7M
2
IRTC icon
iRhythm Holdings
IRTC
+$40.6M
3
PEN icon
Penumbra
PEN
+$32.4M
4
BMY icon
Bristol-Myers Squibb
BMY
+$28M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$27.6M

Sector Composition

Rank Sector Weight
1 Healthcare 81.98%
2 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PEN icon
51
Penumbra
PEN
$12.7B
$20.1M 0.61%
74,351
-125,343
-63% -$32.4M
MOH icon
52
Molina Healthcare
MOH
$10.2B
$16.4M 0.5%
70,088
-31,819
-31% -$7.1M
NVAX icon
53
CALL
Novavax
NVAX
$1.27B
$14.7M 0.45%
81,000
-69,000
-46% -$13.7M
ICUI icon
54
CALL
ICU Medical
ICUI
$4.16B
$14.1M 0.43%
+68,800
New +$14.5M
ADAP
55
DELISTED
Adaptimmune Therapeutics
ADAP
$13.3M 0.41%
2,501,303
-193,466
-7% -$1.11M
ZLAB icon
56
Zai Lab
ZLAB
$2.07B
$13.3M 0.4%
99,375
-7,686
-7% -$1.19M
ICLR icon
57
Icon
ICLR
$12.6B
$12.9M 0.4%
65,863
-55,460
-46% -$10.9M
INNV icon
58
InnovAge Holding
INNV
$1.51B
$11.1M 0.34%
+429,699
New +$10.6M
CNST
59
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$11M 0.34%
469,664
– –
VRTX icon
60
Vertex Pharmaceuticals
VRTX
$123B
$10.1M 0.31%
+46,889
New +$10.3M
CERN
61
DELISTED
Cerner Corp
CERN
$10M 0.31%
+139,569
New +$10.5M
PRDS
62
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$9.96M 0.3%
+1,000,000
New +$10.3M
MDGL icon
63
Madrigal Pharmaceuticals
MDGL
$11.9B
$9.65M 0.29%
+82,534
New +$9.62M
STTK icon
64
Shattuck Labs
STTK
$704M
$9.19M 0.28%
326,813
-60,000
-16% -$2.52M
ALLO icon
65
CALL
Allogene Therapeutics
ALLO
$673M
$8.68M 0.27%
+246,000
New +$8.3M
LONA
66
LeonaBio Inc
LONA
$72.1M
$8.65M 0.26%
47,023
– –
KNTE
67
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$8.23M 0.25%
264,293
-77,612
-23% -$2.7M
SPRY icon
68
ARS Pharmaceuticals
SPRY
$532M
$8.21M 0.25%
188,243
– –
SPRB
69
Spruce Biosciences
SPRB
$128M
$8.13M 0.25%
6,528
-529
-7% -$812K
ITOS
70
DELISTED
iTeos Therapeutics
ITOS
$7.94M 0.24%
+232,216
New +$8.39M
TERN
71
DELISTED
Terns Pharmaceuticals
TERN
$7.24M 0.22%
+329,274
New +$7.22M
CERT icon
72
Certara
CERT
$1.22B
$7.05M 0.22%
258,161
+30,161
+13% +$1M
ONEM
73
DELISTED
1Life Healthcare
ONEM
$6.71M 0.2%
+171,689
New +$8.06M
LUNG icon
74
Pulmonx
LUNG
$85M
$6.25M 0.19%
136,576
-166,055
-55% -$9.52M
HRTX icon
75
CALL
Heron Therapeutics
HRTX
$95.5M
$5.25M 0.16%
+324,100
New +$5.78M
1 2
3
4 5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return

PFM Health Sciences's Q1 2021 Portfolio in Review

As of Q1 2021, PFM Health Sciences held 113 positions worth $3.27B, up 15% from $2.84B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

PFM Health Sciences deployed $259M of net new capital in Q1 2021, opening 28 new positions and adding to 27 existing holdings. Its largest new stake was Neurocrine Biosciences: 1,055,510 shares worth $103M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 79% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Penumbra, an estimated $32.4M trimmed.

  • PFM Health Sciences's largest Q1 2021 buy was Neurocrine Biosciences: 1,055,510 shares worth $103M.
  • PFM Health Sciences added most to Eli Lilly in Q1 2021, an estimated $34.2M increase.
  • PFM Health Sciences's biggest Q1 2021 reduction was Penumbra, cutting an estimated $32.4M.
  • PFM Health Sciences fully exited Elevance Health in Q1 2021, selling an estimated $52.7M.
  • PFM Health Sciences's ten largest holdings make up 37% of its $3.27B portfolio in Q1 2021.
  • PFM Health Sciences opened 28 new positions and closed 27 in Q1 2021.
  • PFM Health Sciences's portfolio value rose 15% quarter-over-quarter to $3.27B.

Based on PFM Health Sciences's 13F filing for Q1 2021, filed 17 May 2021.